본문 바로가기
주메뉴 바로가기

KRH Designated Agency

home >KRH Designated Agency >Asan Medical Center >Introduction

Introduction

Introduction

Asan Medical Center (AMC) is one of the Research-driven Hospitals in Korea, designated by the ministry of Health and Welfare in 2013. AMC is the largest academic medical center in Korea with top-quality medical care and is also making significant R&D investments over the years. The Asan Institute for Life Sciences (AILS) is a global bio-cluster which enables the one-stop system for basic, translational and clinical researches from bench to bedside. AILS also serves as an R&D platform which links between the academia and industry, and is actively working with local and global collaborators including 12 bio-venture companies on campus.

Organization

  • Asna Medical Center
  • Asan Institute for Life Sciences
    • Office for R&D Commercialization
    • Office for Scientific Planning & Coordination
    • Bio-Medical Research Center
    • Clinical Research Center
    • Biomedical Engineering R&D Center
    • Dept. of Convergence Medicine
    • Bio Resource Cente
    • Human Research Protection Center

Research Infrastructure

Core Labs

Equipped with cutting-edge technologies, Core Labs provide analysis and research support for the investigators and collaborators.

Genomics Core, High Throughput Screening Core, Comparative Pathology Core, Flowcytometry Core, Metabolomics Core, Confocal Microscope Core, Genetically Engineered Mouse Core, Laboratory of Animal Research, Animal Imaging Center

Center for Bio-imaging of New Drug Development

C-BiND provides one-stop full bio-imaging services for new drug development throughout the pre-clinical and clinical stages. With its cutting-edge equipment including 9.41 MRI, micro PET/MR, micro CT, Ultrasound, Optical Imaging and Cellular Imaging, the C-BiND provides efficacy and toxicology evaluation in the preclinical stage, imaging-based biodistribution, PK/PD, clinical trials imaging support, and comprehensive consultation.

Bio Resource Center

Bio Resource Center collects and storages vast amount of bio-materials including: cancer tissues & corresponding normal tissues and blood, antibiotics-resistant microorganisms, and bone marrow cells, etc. (total number of patients : 44,851, total number of vials : 343,070, as of July 2014)

Global Center of Excellence in Clinical Trials

  • Our focus : accelerated “Proof of Concept” trials
  • High volume center : the highest patient volume in Korea
  • Outstanding platform technology & Infrastructure
    • - Vast amount of clinical information & specimens in Bio Resource Center
    • - Asan BiomedicaL research Environment(ABLE): CRDW system providing research data extracted from hospital EMR, with full protection of patient privacy
    • - Integrative CTMS and e-IRB system for top efficiency
    • - Advanced technology in radiopharmaceuticals
  • Qualified and experienced global investigators in various disease areas
  • Highly qualified staffs dedicated to clinical trials
  • Quality clinical trials : audits & inspections from global companies and regulatory authorities and active voluntary internal audit

Number of Trials Initiated Each Year (based on the numbers of AMC IRB Approval)

Preclinical and eaRly clInical Support prograM : PRISM

PRISM provides strategic consultations to pharmaceutical companies and venture companies on new drug development throughout the preclinical and early clinical development stages via the “One-stop” service. PRISM’s advisory committee comprises of experts in toxicological pathology, clinical pharmacology, and other clinical specialties.

Cancer Research

Institute for Innovative Cancer Research

As the first-designated hospital in Korea as the government’s research partner, IICR is currently developing personalized medicine with major focus on molecular targeted anti-cancer agent, nano-drug delivery system, and cancer biomarkers, collaborating with 8 domestic pharmaceutical companies.

Center for Development and Commercialization of Anti-cancer Therapeutics

Center for Development and Commercialization of Anti-cancer TherapeuticsCDCAT provides R&D services to industry partners to evaluate efficacy of anti-cancer drug candidates. Pre-clinical services include: assays utilizing patient-derived specimens, animal imaging, toxicity, biomarker analysis, pharmacokinetics as well as conventional animal cancer models.

Asan Center for Cancer Genome Discovery

CCGD has developed patient-derived primary cultured cell lines and xenografts, and is also performing molecular profiling on patients and patient-derived tissues with genomic

Research Personnel

(as of Aug. 2014)

Research Personnel - Research Personnel, Number
Research Personnel Number
Clinical Research Investigator (MD) 578
Basic Research Investigator (PhD) 137
Lab Technicians 637
Total 1,352